TEM Stock Forecast & Price Target

Tempus AI is supported by a differentiated AI-powered precision-medicine platform that has built a 200-petabyte multimodal dataset, connected to more than 3,000 healthcare institutions and used by nearly all of the largest public pharma companies, giving it a durable competitive moat in both diagnostics and data licensing. Its recently expanded relationships with Bristol Myers Squibb and Pathos add up to as much as $192.5 million in aggregate payments, extend monetization beyond oncology into neurology, and validate the company’s land-and-expand model as embedded customers deepen usage over multi-year terms through 2031. The business also has over $1.1 billion of remaining contract value signed as of the end of 2025, while management expects Data & Analytics growth above 30% and margin expansion as higher-value tests and recurring data revenues scale.

Tempus AI is facing a bearish fundamental setup because its valuation depends on trading at a tech-group mean multiple of 4.7x EV/sales on FY26 consensus estimates, which would likely require stronger execution than its current top-line performance suggests. The company operates in a highly competitive healthcare and artificial intelligence landscape, where pressure from established players and emerging startups could limit market share gains and slow adoption across its platform. Its genomics growth also hinges on reimbursement for tests, while the Insights business depends on continued dataset expansion through test volume and health-system relationships, leaving monetization vulnerable if reimbursement falls or customer share is lost.